Disitamab vedotin (RC48), utilizing hertuzumab anti-HER2 antibody, was recently granted conditional approval in China for the treatment of locally advanced or metastatic HER2-overexpressing gastric cancer [168]. This evidence concerns the gene ERBB2 and gastric cancer.